Novel agents positively impact chemotherapy and transplantation in Hodgkin lymphoma

Parastoo B. Dahi, Craig Moskowitz, Sergio A. Giralt, Hillard M. Lazarus

Research output: Contribution to journalReview article

Abstract

Introduction: Majority of patients with Hodgkin lymphoma (HL) can be successfully cured with frontline conventional therapeutics. Approximately 50–60% of those whose disease recur or is refractory to conventional treatment, can be cured with salvage therapies followed by autologous hematopoietic cell transplantation (AHCT). Conventional treatments, however, may cause significant long-term toxicities. Areas covered: This article reviews the treatment advances in HL with the incorporation of novel and targeted agents that are aimed to improve cure rates while reducing toxicities. Expert opinion: Brentuximab vedotin (BV) and checkpoint inhibitors have demonstrated clear clinical benefit in HL. Majority of patients receive BV before or directly after AHCT as part of salvage or maintenance regimens. In patients who relapse after AHCT, checkpoint inhibitors are the treatment of choice, either as a stand-alone therapy or more commonly as a bridge to a potentially curative allogeneic hematopoietic cell transplantation (alloHCT). A multitude of other targeted agents and combinations, as well as cellular and immunotherapeutic in HL, are under investigation.

Original languageEnglish (US)
Pages (from-to)255-264
Number of pages10
JournalExpert Review of Hematology
Volume12
Issue number4
DOIs
StatePublished - Apr 3 2019

Fingerprint

Hodgkin Disease
Transplantation
Cell Transplantation
Drug Therapy
Therapeutics
Salvage Therapy
Expert Testimony
Maintenance
Recurrence

Keywords

  • allogeneic transplant
  • Autologous transplant
  • CAR T cell
  • CD30 directed antibody
  • checkpoint blockade
  • Hodgkin lymphoma
  • immunotherapy
  • novel agents
  • transplant

ASJC Scopus subject areas

  • Hematology

Cite this

Novel agents positively impact chemotherapy and transplantation in Hodgkin lymphoma. / Dahi, Parastoo B.; Moskowitz, Craig; Giralt, Sergio A.; Lazarus, Hillard M.

In: Expert Review of Hematology, Vol. 12, No. 4, 03.04.2019, p. 255-264.

Research output: Contribution to journalReview article

Dahi, Parastoo B. ; Moskowitz, Craig ; Giralt, Sergio A. ; Lazarus, Hillard M. / Novel agents positively impact chemotherapy and transplantation in Hodgkin lymphoma. In: Expert Review of Hematology. 2019 ; Vol. 12, No. 4. pp. 255-264.
@article{5a027323e0654993837226ca356143ee,
title = "Novel agents positively impact chemotherapy and transplantation in Hodgkin lymphoma",
abstract = "Introduction: Majority of patients with Hodgkin lymphoma (HL) can be successfully cured with frontline conventional therapeutics. Approximately 50–60{\%} of those whose disease recur or is refractory to conventional treatment, can be cured with salvage therapies followed by autologous hematopoietic cell transplantation (AHCT). Conventional treatments, however, may cause significant long-term toxicities. Areas covered: This article reviews the treatment advances in HL with the incorporation of novel and targeted agents that are aimed to improve cure rates while reducing toxicities. Expert opinion: Brentuximab vedotin (BV) and checkpoint inhibitors have demonstrated clear clinical benefit in HL. Majority of patients receive BV before or directly after AHCT as part of salvage or maintenance regimens. In patients who relapse after AHCT, checkpoint inhibitors are the treatment of choice, either as a stand-alone therapy or more commonly as a bridge to a potentially curative allogeneic hematopoietic cell transplantation (alloHCT). A multitude of other targeted agents and combinations, as well as cellular and immunotherapeutic in HL, are under investigation.",
keywords = "allogeneic transplant, Autologous transplant, CAR T cell, CD30 directed antibody, checkpoint blockade, Hodgkin lymphoma, immunotherapy, novel agents, transplant",
author = "Dahi, {Parastoo B.} and Craig Moskowitz and Giralt, {Sergio A.} and Lazarus, {Hillard M.}",
year = "2019",
month = "4",
day = "3",
doi = "10.1080/17474086.2019.1593135",
language = "English (US)",
volume = "12",
pages = "255--264",
journal = "Expert Review of Hematology",
issn = "1747-4086",
publisher = "Expert Reviews Ltd.",
number = "4",

}

TY - JOUR

T1 - Novel agents positively impact chemotherapy and transplantation in Hodgkin lymphoma

AU - Dahi, Parastoo B.

AU - Moskowitz, Craig

AU - Giralt, Sergio A.

AU - Lazarus, Hillard M.

PY - 2019/4/3

Y1 - 2019/4/3

N2 - Introduction: Majority of patients with Hodgkin lymphoma (HL) can be successfully cured with frontline conventional therapeutics. Approximately 50–60% of those whose disease recur or is refractory to conventional treatment, can be cured with salvage therapies followed by autologous hematopoietic cell transplantation (AHCT). Conventional treatments, however, may cause significant long-term toxicities. Areas covered: This article reviews the treatment advances in HL with the incorporation of novel and targeted agents that are aimed to improve cure rates while reducing toxicities. Expert opinion: Brentuximab vedotin (BV) and checkpoint inhibitors have demonstrated clear clinical benefit in HL. Majority of patients receive BV before or directly after AHCT as part of salvage or maintenance regimens. In patients who relapse after AHCT, checkpoint inhibitors are the treatment of choice, either as a stand-alone therapy or more commonly as a bridge to a potentially curative allogeneic hematopoietic cell transplantation (alloHCT). A multitude of other targeted agents and combinations, as well as cellular and immunotherapeutic in HL, are under investigation.

AB - Introduction: Majority of patients with Hodgkin lymphoma (HL) can be successfully cured with frontline conventional therapeutics. Approximately 50–60% of those whose disease recur or is refractory to conventional treatment, can be cured with salvage therapies followed by autologous hematopoietic cell transplantation (AHCT). Conventional treatments, however, may cause significant long-term toxicities. Areas covered: This article reviews the treatment advances in HL with the incorporation of novel and targeted agents that are aimed to improve cure rates while reducing toxicities. Expert opinion: Brentuximab vedotin (BV) and checkpoint inhibitors have demonstrated clear clinical benefit in HL. Majority of patients receive BV before or directly after AHCT as part of salvage or maintenance regimens. In patients who relapse after AHCT, checkpoint inhibitors are the treatment of choice, either as a stand-alone therapy or more commonly as a bridge to a potentially curative allogeneic hematopoietic cell transplantation (alloHCT). A multitude of other targeted agents and combinations, as well as cellular and immunotherapeutic in HL, are under investigation.

KW - allogeneic transplant

KW - Autologous transplant

KW - CAR T cell

KW - CD30 directed antibody

KW - checkpoint blockade

KW - Hodgkin lymphoma

KW - immunotherapy

KW - novel agents

KW - transplant

UR - http://www.scopus.com/inward/record.url?scp=85064744956&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064744956&partnerID=8YFLogxK

U2 - 10.1080/17474086.2019.1593135

DO - 10.1080/17474086.2019.1593135

M3 - Review article

C2 - 30874456

AN - SCOPUS:85064744956

VL - 12

SP - 255

EP - 264

JO - Expert Review of Hematology

JF - Expert Review of Hematology

SN - 1747-4086

IS - 4

ER -